Mateon Therapeutics (OTCMKTS: MATN) and Soligenix (NASDAQ:SNGX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, valuation, profitability, institutional ownership, analyst recommendations, risk and dividends.
Volatility and Risk
Mateon Therapeutics has a beta of 2.07, meaning that its share price is 107% more volatile than the S&P 500. Comparatively, Soligenix has a beta of 0.54, meaning that its share price is 46% less volatile than the S&P 500.
Earnings & Valuation
This table compares Mateon Therapeutics and Soligenix’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Mateon Therapeutics||N/A||N/A||-$13.65 million||($0.51)||-0.49|
|Soligenix||$5.43 million||2.99||-$7.14 million||($1.38)||-1.35|
Soligenix has higher revenue and earnings than Mateon Therapeutics. Soligenix is trading at a lower price-to-earnings ratio than Mateon Therapeutics, indicating that it is currently the more affordable of the two stocks.
This is a breakdown of recent recommendations and price targets for Mateon Therapeutics and Soligenix, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Mateon Therapeutics presently has a consensus target price of $1.67, indicating a potential upside of 566.67%. Soligenix has a consensus target price of $4.00, indicating a potential upside of 115.05%. Given Mateon Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Mateon Therapeutics is more favorable than Soligenix.
Insider & Institutional Ownership
11.9% of Soligenix shares are held by institutional investors. 4.5% of Mateon Therapeutics shares are held by insiders. Comparatively, 5.0% of Soligenix shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
This table compares Mateon Therapeutics and Soligenix’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
About Mateon Therapeutics
Mateon Therapeutics, Inc., formerly OXiGENE, Inc., is a biopharmaceutical company. The Company is focused on the development of vascular disrupting agents (VDAs) for the treatment of cancer. The Company is engaged in developing two clinical stage investigational drugs: VDAs-CA4P and OXi4503. Its lead compound is CA4P, which is also known as combretastatin A4-phosphate, fosbretabulin tromethamine, fosbretabulin and ZYBRESTAT. VDAs selectively targets the vasculature of cancer tumors and obstructs a tumor’s blood supply without disrupting the blood supply to normal tissues. VDAs are in a class of drugs called vascular targeted therapies (VTTs), which also includes anti-angiogenic agents (AAs). CA4P is a reversible tubulin binding agent that selectively targets the endothelial cells that make up the blood vessel walls in solid tumors. The Company is pursuing the development of a product candidate, OXi4503, which is a dual-mechanism VDA.
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates through two segments, BioTherapeutics and Vaccines/BioDefense. The BioTherapeutics segment develops SGX301, a photodynamic therapy, which is in Phase III clinical trial to treat cutaneous T-cell lymphoma; and proprietary formulations of oral beclomethasone 17,21-dipropionate for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation, including pediatric Crohn's disease and acute radiation enteritis. This segment also offers SGX942, an innate defense regulator technology that has completed Phase II clinical trial to treat oral mucositis in head and neck cancer. The Vaccines/BioDefense segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase IB clinical trial for the treatment of vaccine against ricin toxin poisoning; VeloThrax, an anthrax vaccine candidate; OrbeShield, a GI acute radiation syndrome (GI ARS) therapeutic candidate, which is in pre-clinical stage to treat therapeutics against GI ARS; and SGX943, a melioidosis therapeutic candidate that is in pre-clinical stage for the treatment of melioidosis. Its vaccines are supported by its ThermoVax, a heat stabilization technology. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was founded in 1987 and is headquartered in Princeton, New Jersey.
Receive News & Ratings for Mateon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mateon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.